Table 2. Baseline characteristics of participants, across all 3 tertiles of SOMAScan-derived NT-proBNP in TOPCAT.
Numbers represent Mean (SD), Median (IQR) or counts (%)
| Demographics | Lowest tertile (n=73) | Middle tertile (n=72) | Highest tertile (n=73) | P value |
|---|---|---|---|---|
| SOMAScan NT-proBNP levels | 773-8520 | 8520-15465 | 15465-60376 | |
| Age, years | 68 (60-75.3) | 72 (66-79) | 78 (66.8-82) | 0.0003 |
| Male sex | 37 (50.68%) | 44 (61.11%) | 41 (56.16%) | 0.4492 |
| Race | 0.4363 | |||
| White | 60 (82.19%) | 61 (84.72%) | 67 (91.78%) | |
| Black | 12 (16.44%) | 9 (12.50%) | 5 (6.85%) | |
| Asian | 0 (0.00%) | 1 (1.39%) | 0 (0.00%) | |
| Other | 1 (1.37%) | 1 (1.39%) | 1 (1.37%) | |
| Medical History | ||||
| Myocardial infarction | 18 (24.66%) | 18 (25.00%) | 13 (17.81%) | 0.5027 |
| Stroke | 4 (5.48%) | 5 (6.94%) | 6 (8.22%) | 0.8072 |
| CABG | 15 (20.55%) | 20 (27.78%) | 23 (31.51%) | 0.3134 |
| PCI | 22 (30.14%) | 18 (25.00%) | 16 (21.92%) | 0.5173 |
| COPD | 10 (13.70%) | 8 (11.11%) | 6 (8.22%) | 0.5713 |
| Hypertension | 71 (97.26%) | 64 (88.89%) | 71 (97.26%) | 0.0388 |
| AF | 22 (30.14%) | 32 (44.44%) | 54 (73.97%) | <0.0001 |
| Diabetes | 40 (54.79%) | 30 (41.67%) | 33 (45.21%) | 0.2605 |
| Insulin use | 21 (28.77%) | 16 (22.22%) | 6 (8.22%) | 0.0062 |
| Smoking | 37 (56.06%) | 47 (69.12%) | 43 (60.56%) | 0.2849 |
| eGFR, mL/min/1.73m2 | 66.3 (40-86.6) | 64.7 (46.5-82.9) | 63.4 (42.3-84.5) | 0.6853 |
| Hematocrit, % | 38 (36-41.3) | 39.4 (35.8-42) | 39 (35.7-41.2) | 0.6173 |
| BMI, kg/m2 | 35.3 (30.7-41.1) | 32.6 (28.8-35.5) | 31.6 (27.2-35.4) | 0.0012 |
| Systolic BP, mmHg | 126 (115-137) | 122 (116-133) | 124 (117-133) | 0.8064 |
| Diastolic BP, mmHg | 70.2 (60-80.4) | 70.4 (59.5-81.3) | 67.7 (56.2-79.2) | 0.2676 |
| Medication use | ||||
| Beta blocker | 58 (79.45%) | 65 (90.28%) | 58 (79.45%) | 0.1346 |
| Calcium channel blocker | 30 (41.10%) | 29 (40.28%) | 26 (35.62%) | 0.7651 |
| ACEI/ARB | 62 (84.93%) | 44 (61.11%) | 58 (79.45%) | 0.0024 |
| Aspirin | 49 (67.12%) | 48 (66.67%) | 38 (52.05%) | 0.1033 |
| Statin | 58 (79.45%) | 51 (70.83%) | 52 (71.23%) | 0.4097 |
| KCCQ overall summary score | 62.5 (44.7-81.8) | 70.3 (51.4-86.9) | 59.5 (39.6-75.3) | 0.0531 |
| KCCQ clinical summary score | 64.6 (45.8-82.6) | 65.6 (44.5-84.6) | 62.5 (45.8-77.6) | 0.3133 |
|
Participants with available NT-
proBNP measurement in trial * |
15 | 26 | 30 | |
| Trial NT-proBNP level, ng/mL | 557 (356-757) | 876 (645-1106) | 1853 (1402-2303) | <0.0001 |
|
Participants with available BNP
measurement in trial * |
29 | 29 | 31 | |
| Trial BNP level, ng/mL | 180 (131-229) | 211 (154-269) | 477 (352-602) | <0.0001 |
ACEi/ARB= Angiotensin Converting Enzyme inhibitor/Angiotensin Receptor Blocker; AF=Atrial Fibrillation; BMI=Body Mass Index; CABG=Coronary Artery Bypass Graft; COPD=Chronic Obstructive Pulmonary Disease; BP=Blood Pressure; eGFR=estimated Glomerular Filtration Rate; KCCQ=Kansas City Cardiomyopathy Questionnaire, NT-proBNP= N-terminal (NT)-pro hormone BNP, PCI= Percutaneous Coronary Intervention.
*
within 30 days prior to eligibility